Abbott Laboratories posted first-quarter earnings that edged past analysts’ estimates but a protracted slump in one business line and a dilutive acquisition sent shares tumbling on Thursday. Abbott ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results